TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15748120

Group type: EXPERIMENTAL
Intervention: Quadriceps exercise group
Number of subjects: 103

Group type: COMPARATOR
Intervention: No quadriceps exercise group
Number of subjects: 103
Study: 12638641

Group type: EXPERIMENTAL
Intervention: 5-HT-selective pharmacotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9827783

Group type: EXPERIMENTAL
Intervention: Ardeparin with a 2‐day hospitalization
Number of subjects: 80

Group type: COMPARATOR
Intervention: Unfractionated heparin sodium with a 5‐day hospitalization
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ardeparin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ardeparin and Unfractionated heparin
Number of subjects: 80
Study: 7712665

Group type: EXPERIMENTAL
Intervention: Exercise (20 minutes)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Food intake (standardized meal)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 10
Study: 2970788

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 29209778

Group type: EXPERIMENTAL
Intervention: Prourokinase injection (20 mg intravenously followed by 30 mg intravenous infusion within 30 min)
Number of subjects: 1851

Group type: EXPERIMENTAL
Intervention: Prourokinase injection
Number of subjects: 1851
Study: 27655440

Group type: COMPARATOR
Intervention: leucine-10g
Number of subjects: 12

Group type: COMPARATOR
Intervention: leucine-5g
Number of subjects: 12

Group type: COMPARATOR
Intervention: isoleucine-10g
Number of subjects: 12

Group type: COMPARATOR
Intervention: isoleucine-5g
Number of subjects: 12
Study: 25129820

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control (no intravenous metoprolol)
Number of subjects: 270
Study: 23514019

Group type: EXPERIMENTAL
Intervention: Educational intervention detailing risks and safe alternatives to benzodiazepines
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 250
Study: 21540395

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine co‐formulated (AAcf)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine co‐packaged (AAcp)
Number of subjects: 285
Study: 19399951

Group type: EXPERIMENTAL
Intervention: Educational leaflet
Number of subjects: 1209
Study: 16720082

Group type: EXPERIMENTAL
Intervention: Voucher-based incentives delivered contingent on biochemically-verified abstinence
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control condition wherein incentives were given independent of smoking status
Number of subjects: 129
Study: 15476300

Group type: EXPERIMENTAL
Intervention: Intraobserver measurements of fetal biparietal diameter (BPD)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Intraobserver measurements of abdominal circumference (AC)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Intraobserver measurements of head circumference (HC)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Intraobserver measurements of femur length (FL)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Interobserver measurements of fetal biparietal diameter (BPD)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Interobserver measurements of abdominal circumference (AC)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Interobserver measurements of head circumference (HC)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Interobserver measurements of femur length (FL)
Number of subjects: 122
Study: 11758232

Group type: EXPERIMENTAL
Intervention: CBS 844ins68
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: MS A2756G
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: MTHFR C677T
Number of subjects: 275

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 275
Study: 9154893

Group type: EXPERIMENTAL
Intervention: Inhaled leukotriene B4 (17.6 +/- 3.4 microg for normal subjects; 18.2 +/- 1.9 microg for asthmatics)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7966812

Group type: EXPERIMENTAL
Intervention: Ulcerated limbs (CVI class 3)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Contralateral 'normal' limbs (CVI class 0)
Number of subjects: 120
Study: 4074450

Group type: EXPERIMENTAL
Intervention: 150 mg proglumetacin t.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50 mg indometacin t.i.d.
Number of subjects: 0
Study: 31945149

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (A+AVD)
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (A+AVD) in PET2- patients aged <60 years
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in PET2- patients aged <60 years
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (A+AVD) in PET2+ patients aged <60 years
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in PET2+ patients aged <60 years
Number of subjects: 1334
Study: 29452985

Group type: EXPERIMENTAL
Intervention: Postural hygiene training and kinesiotherapy for 12 weeks, 2 days a week, 1 hour per session
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Home adaptation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 26954273

Group type: EXPERIMENTAL
Intervention: Therapist-selected nonthrust manipulation
Number of subjects: 63

Group type: COMPARATOR
Intervention: Prescriptively selected nonthrust manipulation
Number of subjects: 63
Study: 24635880

Group type: EXPERIMENTAL
Intervention: 3-monthly monitoring
Number of subjects: 2215

Group type: COMPARATOR
Intervention: 6-monthly monitoring
Number of subjects: 2215

Group type: COMPARATOR
Intervention: Cost-effectiveness of 6-monthly monitoring
Number of subjects: 2215
Study: 22076708

Group type: EXPERIMENTAL
Intervention: CTLA4: A49G [rs231775]
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: XRCC1: Arg339Gln [rs25487]
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: ERCC2: Lys751Gln [rs13181]
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: TP53: Arg72Pro [rs1042522]
Number of subjects: 531
Study: 22128444

Group type: EXPERIMENTAL
Intervention: Stryker Disc Dekompressor for aspiration of disc material (Group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epidural steroid/local anesthetic injection (Group 2)
Number of subjects: 50
Study: 17927726

Group type: EXPERIMENTAL
Intervention: Intramuscular route (Group 1): ketamine (6 mg/kg), midazolam (0.05 mg/kg), atropine (0.02 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral route (Group 2): ketamine (10 mg/kg), midazolam (0.2 mg/kg), atropine (0.05 mg/kg)
Number of subjects: 60
Study: 17477927

Group type: EXPERIMENTAL
Intervention: Stage II POP with prior surgery
Number of subjects: 314

Group type: COMPARATOR
Intervention: More advanced POP
Number of subjects: 314
Study: 15289374

Group type: EXPERIMENTAL
Intervention: 0.05 mmol/kg gadopentetate dimeglumine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 0.10 mmol/kg gadopentetate dimeglumine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 0.15 mmol/kg gadopentetate dimeglumine
Number of subjects: 99
Study: 11728258

Group type: EXPERIMENTAL
Intervention: Perindopril (plus indapamide)
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study: 15321310

Group type: EXPERIMENTAL
Intervention: Fentanyl 25 microg
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Morphine 100 microg
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Fentanyl 25 microg and Morphine 100 microg
Number of subjects: 116

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 116
Study: 1403591

Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peroxyborate rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Toothpaste slurry rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetylpyridinium chloride rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prebrushing detergent rinse
Number of subjects: 0
Study: 3894200

Group type: EXPERIMENTAL
Intervention: Esophageal variceal sclerotherapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study: 31599468

Group type: EXPERIMENTAL
Intervention: Sequential Multiple Assignment Randomized Trial (SMART) design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pragmatic clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pragmatic nursing trials using SMART designs
Number of subjects: 0
Study: 28686959

Group type: EXPERIMENTAL
Intervention: Simulated bed bath scenario
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (traditional teaching)
Number of subjects: 58
Study: 26518090

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 727

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 727

Group type: COMPARATOR
Intervention: ICS boost
Number of subjects: 727
Study: 23509932

Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing (MI) and anticipatory guidance (AG) approaches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care group (standard early oral health screening program; 'lift the lip')
Number of subjects: 0
Study: 21786489

Group type: EXPERIMENTAL
Intervention: Continuous infusion of normal saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Syringe push method of normal saline
Number of subjects: 0
Study: 19078947

Group type: EXPERIMENTAL
Intervention: Calcium channel alpha2delta ligands (lead compound at approximately 30 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium channel alpha2delta ligands (backup compound at >600 mg)
Number of subjects: 0
Study: 16877536

Group type: EXPERIMENTAL
Intervention: Highest quintile of body mass index (BMI)
Number of subjects: 28983

Group type: EXPERIMENTAL
Intervention: Cluster of three IRS-related conditions (hypertension, BMI >/=25 kg/m(2), HDL cholesterol <40 mg/dl)
Number of subjects: 28983
Study: 14503055

Group type: EXPERIMENTAL
Intervention: Tiaoxin Recipe (TXR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bushen Recipe (BSR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Donepezil (Dp)
Number of subjects: 60
Study: 10851645

Group type: EXPERIMENTAL
Intervention: 2.4 million U extencilline
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 1.2 million U extencilline
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 1.5 million U bicillin-5
Number of subjects: 33
Study: 9088591

Group type: EXPERIMENTAL
Intervention: Candoxatril
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Candoxatril/Captopril
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8256735

Group type: EXPERIMENTAL
Intervention: Left-sided approach
Number of subjects: 21

Group type: COMPARATOR
Intervention: Right-sided approach
Number of subjects: 21
Study: 3895921

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 704

Group type: COMPARATOR
Intervention: Cefamandole or Tobramycin plus Ticarcillin
Number of subjects: 704

Group type: COMPARATOR
Intervention: Tobramycin and Ticarcillin
Number of subjects: 704
Study: 29860917

Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy
Number of subjects: 6711

Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 6711

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 6711
Study: 26280319

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 24
Study: 25208569

Group type: EXPERIMENTAL
Intervention: Web-based modality
Number of subjects: 253

Group type: COMPARATOR
Intervention: Manual-based modality
Number of subjects: 253
Study: 22261295

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 90
Study: 20417659

Group type: EXPERIMENTAL
Intervention: Cannabis with high δ9-THC contents (up to 69.4mg THC)
Number of subjects: 24
Study: 17609247

Group type: EXPERIMENTAL
Intervention: Mifepristone (5 mg daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Levonorgestrel (0.03 mg progestogen-only pill)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Mifepristone (5 mg daily) with condoms
Number of subjects: 96
Study: 16216596

Group type: EXPERIMENTAL
Intervention: DASH diet rich in fruits, vegetables and low-fat dairy products, reduced in fat (27%), saturated fat (7%), and cholesterol (150 mg/day) for 3 months
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 103
Study: 12220692

Group type: EXPERIMENTAL
Intervention: Polish patients with ischaemic stroke
Number of subjects: 17370

Group type: COMPARATOR
Intervention: Other IST countries patients with ischaemic stroke
Number of subjects: 17370

Group type: EXPERIMENTAL
Intervention: Polish patients with coronary heart disease
Number of subjects: 17370

Group type: EXPERIMENTAL
Intervention: Polish patients with pulmonary embolism
Number of subjects: 17370

Group type: EXPERIMENTAL
Intervention: Polish patients younger than 75 years
Number of subjects: 17370

Group type: EXPERIMENTAL
Intervention: Polish female patients
Number of subjects: 17370

Group type: EXPERIMENTAL
Intervention: Polish patients alert at onset
Number of subjects: 17370

Group type: EXPERIMENTAL
Intervention: Polish patients with partial anterior circulation syndrome (PACS)
Number of subjects: 17370

Group type: EXPERIMENTAL
Intervention: Polish patients with lacunar syndrome (LACS)
Number of subjects: 17370

Group type: EXPERIMENTAL
Intervention: Polish patients without atrial fibrillation (AF)
Number of subjects: 17370

Group type: EXPERIMENTAL
Intervention: Polish patients on aspirin before stroke
Number of subjects: 17370
Study: 9686700

Group type: EXPERIMENTAL
Intervention: Lispro (Group I, n = 15)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Lispro (Group II, n = 18)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Soluble (Group III, n = 12)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Soluble injected at mealtimes (Group IV, n = 24)
Number of subjects: 69
Study: 8120559

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron plus dexamethasone
Number of subjects: 275

Group type: COMPARATOR
Intervention: Intravenous ondansetron alone
Number of subjects: 275
Study: 2638180

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan/PVM/MA copolymer/NaF dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0
Study: 1136689

Group type: EXPERIMENTAL
Intervention: Decelerating flow
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Constant flow
Number of subjects: 8

Group type: COMPARATOR
Intervention: Accelerating flow
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Gas exchange studies (all flow patterns)
Number of subjects: 8
Study: 29768292

Group type: EXPERIMENTAL
Intervention: Infrared vein visualization device support
Number of subjects: 54
Study: 31290715

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugated vaccine (PCV13)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Both vaccines (PPV23 and PCV13)
Number of subjects: 136
Study: 29032957

Group type: EXPERIMENTAL
Intervention: Consecutive-day dosing of 60 mg iron at 0800 h for 14 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alternate-day dosing of 60 mg iron at 0800 h for 28 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of 120 mg iron at 0800 h for 3 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Twice-daily divided dosing of 60 mg iron at 0800 h and 1700 h for 3 days
Number of subjects: 60
Study: 24385202

Group type: EXPERIMENTAL
Intervention: Anti-TNFα therapy (infliximab and etanercept)
Number of subjects: 0
Study: 24070742

Group type: EXPERIMENTAL
Intervention: MI‐via‐CALC
Number of subjects: 45

Group type: COMPARATOR
Intervention: LEARN Program
Number of subjects: 45
Study: 21469401

Group type: EXPERIMENTAL
Intervention: Chemomechanical (papain‐based gel followed by curette)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Mechanical (curette‐‐control group)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: SB (Adper Single Bond 2)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: SE (Clearfil SE Bond)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: TriS (Clearfil Tri‐S Bond)
Number of subjects: 84
Study: 19737848

Group type: EXPERIMENTAL
Intervention: Endoscopic stenting (ERCP with sphincterotomy and PD stenting)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic stenting
Number of subjects: 0
Study: 17013572

Group type: EXPERIMENTAL
Intervention: IORT with electrons at 20 Gy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: IORT with electrons at 22 Gy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: IORT with electrons at 24 Gy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: IORT with electrons
Number of subjects: 47
Study: 15556056

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 3034

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3034
Study: 10998741

Group type: COMPARATOR
Intervention: Local anesthetic only
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Sarapin added to local anesthetic
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Depo-medrol along with Sarapin
Number of subjects: 180
Study: 9625848

Group type: EXPERIMENTAL
Intervention: LDLR positive (LDLR+)
Number of subjects: 90

Group type: COMPARATOR
Intervention: LDLR negative (LDLR-)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Absence of LDLR
Number of subjects: 90
Study: 7877082

Group type: EXPERIMENTAL
Intervention: Subpedicle connective tissue graft
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (untreated recessions)
Number of subjects: 15
Study: 3138446

Group type: COMPARATOR
Intervention: Gauze dressings changed three times per week
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: OpSite dressings changed every 7th day (OpS-7)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: OpSite dressings changed every 10th day (OpS-10)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: OpSite dressings changed twice weekly (OpS-ICU)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Septicemia attributable to causes apart from catheter sepsis
Number of subjects: 168
Study: 31160034

Group type: EXPERIMENTAL
Intervention: S aureus colonization
Number of subjects: 312
Study: 29252120

Group type: EXPERIMENTAL
Intervention: Changing the way stories frame depression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Earlier scholarship
Number of subjects: 0
Study: 27399068

Group type: EXPERIMENTAL
Intervention: Soft lateral wedge arch support (LWAS) insoles
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rigid lateral wedge arch support (LWAS) insoles
Number of subjects: 90
Study: 24608200

Group type: EXPERIMENTAL
Intervention: Trastuzumab (9 weeks)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: No trastuzumab
Number of subjects: 1010
Study: 23114388

Group type: EXPERIMENTAL
Intervention: Exercise intervention (3 × 20 minutes per week for 12 weeks)
Number of subjects: 67
Study: 19602839

Group type: EXPERIMENTAL
Intervention: BCAA supplementation (isoleucine:leucine:valine=1:2.3:1.2) at 0.1 g/kg body weight 15 min before squat exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (dextrin) at 0.1 g/kg body weight 15 min before squat exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 0
Study: 17804312

Group type: EXPERIMENTAL
Intervention: Hand/rotary technique
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hand/rotary/ultrasound technique
Number of subjects: 40
Study: 14678375

Group type: EXPERIMENTAL
Intervention: Intravesical prostaglandin E2 (1.5 mg in 20 mL 0.9% saline) plus oral bethanechol chloride (50 mg four times daily) for 6 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline instillation plus placebo tablets for 6 weeks
Number of subjects: 19
Study: 12403032

Group type: EXPERIMENTAL
Intervention: Rovamycin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Augmentin
Number of subjects: 40
Study: 10210973

Group type: EXPERIMENTAL
Intervention: Two nucleoside analogues and one protease inhibitor
Number of subjects: 61
Study: 7596211

Group type: EXPERIMENTAL
Intervention: Continuous treatment teams with extensive training in in vivo treatment
Number of subjects: 185

Group type: COMPARATOR
Intervention: Case management program emphasizing office-based treatment
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Mixed prospective/retrospective payment
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Overall services provided
Number of subjects: 185
Study: 2196060

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 77

Group type: COMPARATOR
Intervention: Cyclosporin A
Number of subjects: 77
Study: 656357

Group type: EXPERIMENTAL
Intervention: Pilocarpine in an oily solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pilocarpine in aqueous solution
Number of subjects: 0
Study: 6797663

Group type: EXPERIMENTAL
Intervention: Alternative drugs (specific drugs not mentioned)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Treatment-free interval between drugs
Number of subjects: 88

Group type: COMPARATOR
Intervention: Gold, penicillamine, levamisole (as first second-line drug)
Number of subjects: 88
Study: 30719351

Group type: EXPERIMENTAL
Intervention: Diaphragmatic stretch technique
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Manual diaphragm release technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of both techniques
Number of subjects: 20
Study: 28486495

Group type: EXPERIMENTAL
Intervention: Childhood cancer survivors
Number of subjects: 21297